Should You Buy Co-Diagnostics Inc (CODX) Stock After it Has Gained 20.47% in a Week?

Co-Diagnostics Inc (CODX) stock is higher by 20.47% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Co-Diagnostics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CODX!

See Full CODX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CODX Stock Today?

Co-Diagnostics Inc (CODX) stock has gained 10.07% while the S&P 500 is down -0.15% as of 1:56 PM on Thursday, Nov 16. CODX is up $0.14 from the previous closing price of $1.39 on volume of 180,560 shares. Over the past year the S&P 500 is higher by 12.64% while CODX is down -58.42%. CODX lost -$1.45 per share in the over the last 12 months. To screen for more stocks like Co-Diagnostics Inc click here.

More About Co-Diagnostics Inc

Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV. The company's diagnostics systems enable very rapid, low-cost, sophisticated molecular testing for organisms and genetic diseases by greatly automating historically complex procedures in both the development and administration of tests. Click Here to get the full Stock Report for Co-Diagnostics Inc stock.